SCHEMBL205560

SCHEMBL205560

CCCCCCCOc1ccc(Nc2nc(-c3ccccc3OC)cs2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.64
HPGDS O60760 1/20 0.60
AMY1A P0DUB6 1/20 0.55
PTGS2 P35354 2/20 0.54
MEN1 O00255 8/20 0.51
KMT2A Q03164 8/20 0.51
MAPT P10636 7/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
GAA P10253 5/20 0.51
RAB9A P51151 5/20 0.51
ALOX5 P09917 3/20 0.51
NFKB1 P19838 2/20 0.51
NFKB2 Q00653 2/20 0.51
RELA Q04206 2/20 0.51
RECQL P46063 1/20 0.51
NAMPT P43490 1/20 0.50
CYP1A2 P05177 2/20 0.49
CYP1A1 P04798 1/20 0.49
CYP1B1 Q16678 1/20 0.49
CSNK2A1 P68400 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206944 1.00 VCP (0.64) VCPHPGDSAMY1APTGS2MEN1
SCHEMBL206445 0.89 CSNK2A1 (0.53) VCPAMY1APTGS2MEN1KMT2A
SCHEMBL12297935 0.88 VCP (0.71) VCPHPGDSAMY1APTGS2MEN1
SCHEMBL248273 0.86 AMY1A (0.69) VCPHPGDSAMY1AMEN1KMT2A
SCHEMBL250132 0.86 AMY1A (0.69) VCPHPGDSAMY1AMEN1KMT2A
SCHEMBL12297184 0.84 VCP (0.79) VCPHPGDSAMY1APTGS2MEN1
SCHEMBL207091 0.84 RAB9A (0.66) VCPAMY1APTGS2MEN1KMT2A
SCHEMBL208212 0.83 MEN1 (0.52) VCPAMY1APTGS2MEN1KMT2A
SCHEMBL205162 0.83 PTGS2 (0.73) VCPPTGS2MEN1KMT2AMAPT
SCHEMBL207938 0.83 PTGS2 (0.73) VCPPTGS2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 VCP 1270/4885HPGDS 3907/4885AMY1A 527/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 VCP 1270/4885HPGDS 3907/4885AMY1A 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.